Bond Pet Foods makes pet food from real animal protein, without the animal by working with biotechnology. Bond Pet Foods develops meat proteins obtained from animal cells (no slaughter required) and natural microbes. It is fed a nutrient-rich broth of vitamins, sugars, and minerals in fermentation tanks, without the pharmaceuticals. Bond Pet Foods was founded on 2015 and is headquartered in Boulder, Colorado.
Developer of a multi-omic biomarker measurement tool designed to understand the genetic, environmental, lifestyle and clinical factors that contribute to individual health and wellness. The company provides a quantitative and digital spatial platform that provides nucleic acid and protein assay sensitivity and simultaneous analyte detection while maintaining a simple sample-to-answer workflow, enabling researchers to analyze viral and bacterial targets, mutations, deletions and gene and protein expression more efficiently.
Epitel is building a brain health management platform backed by powerful data analytics, starting with seizure detection.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.
SimBioSys, Inc. is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
InterVenn Biosciences Inc. is a biotechnology company that specializes in artificial intelligence-based mass spectrometry technology for glycoproteomics. Founded in 2017 and headquartered in South San Francisco, California, with additional offices in the Philippines, Malaysia, and Australia, InterVenn focuses on the identification, quantification, and classification of glycoproteomic signals in human blood and tissue. Its VISTA platform is the first commercially available system that assesses protein glycosylation in a site-specific manner, enabling the discovery of biomarkers for various conditions, including cancers, autoimmunity, fibrosis, and neurodegeneration. The company's technology aims to facilitate early cancer detection and improve patient care through actionable insights derived from glycoproteomic analysis.
Stemson Therapeutics, LLC operates as a cell therapy company that helps to restore natural hair. The company produces cells required to regenerate hair follicles using the novel cell engineering process. Its products include the stemson solution, a solution that generates novo follicles using induced pluripotent stem cells (iPSC) to grow new Dermal Papilla. The company was founded in 2018 and is based in LA Jolla, California.
BloodQ develops an analytical platform designed for cancer drug treatment. Its platform captures disease molecular signals in circulating DNA to improve sensitivity, specificity, and timing in diagnostic and disease management, thereby providing patients personalized cancer treatment.
Developer of neurostimulation products designed to improve human health and performance. The company's products target sleep-related conditions that modulate the activity of the brain structures, enabling patients to improve symptoms of central nervous system disorders for patients.
BRAINBox Solutions, Inc. specializes in developing and manufacturing diagnostic tests for traumatic brain injury (TBI), particularly mild traumatic brain injury. Based in Richmond, Virginia, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive testing, and point-of-care instruments to provide objective evidence of injury and predict patient recovery. Its quantitative tests combine injury-related blood protein biomarkers with computerized neurological assessments, enhancing the accuracy of diagnoses and prognoses. Founded in 2002, BRAINBox Solutions aims to lead the industry in TBI assessment and management through innovative solutions.
InterVenn Biosciences Inc. is a biotechnology company that specializes in artificial intelligence-based mass spectrometry technology for glycoproteomics. Founded in 2017 and headquartered in South San Francisco, California, with additional offices in the Philippines, Malaysia, and Australia, InterVenn focuses on the identification, quantification, and classification of glycoproteomic signals in human blood and tissue. Its VISTA platform is the first commercially available system that assesses protein glycosylation in a site-specific manner, enabling the discovery of biomarkers for various conditions, including cancers, autoimmunity, fibrosis, and neurodegeneration. The company's technology aims to facilitate early cancer detection and improve patient care through actionable insights derived from glycoproteomic analysis.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
InterVenn Biosciences Inc. is a biotechnology company that specializes in artificial intelligence-based mass spectrometry technology for glycoproteomics. Founded in 2017 and headquartered in South San Francisco, California, with additional offices in the Philippines, Malaysia, and Australia, InterVenn focuses on the identification, quantification, and classification of glycoproteomic signals in human blood and tissue. Its VISTA platform is the first commercially available system that assesses protein glycosylation in a site-specific manner, enabling the discovery of biomarkers for various conditions, including cancers, autoimmunity, fibrosis, and neurodegeneration. The company's technology aims to facilitate early cancer detection and improve patient care through actionable insights derived from glycoproteomic analysis.
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
Intabio, Inc. is a biotechnology company focused on enhancing the development and manufacturing processes of biotherapeutic drugs through its innovative analytical solutions. Founded in 2015 and based in Newark, California, Intabio has developed the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of intact biotherapeutic proteins. This platform enables real-time characterization of protein isoforms, allowing for the identification of structural modifications that may affect drug efficacy and safety. By providing early product quality characterization and improving throughput, the Blaze system addresses critical challenges faced by biopharmaceutical developers, who often encounter limitations with traditional testing methods. Intabio's technology integrates multiple analytical techniques to facilitate a comprehensive analysis of biologics, ultimately streamlining the development process and reducing the risk of costly delays and missteps.
Akadeum Life Sciences, Inc. is a life sciences company headquartered in Ann Arbor, Michigan, that specializes in manufacturing microbubble cell separation products. Founded in 2014, the company focuses on isolating mammalian and bacterial cells from complex mixtures, offering a range of products including T cell and B cell isolation kits for human and mouse cells. Additionally, Akadeum provides depletion microbubbles for red blood cell removal and streptavidin microbubbles for targeting and capturing various biological entities. Its innovative approach utilizes buoyancy-activated cell sorting, which employs microscopic microbubbles to effectively isolate target cells by floating them to the surface of liquid samples. These advancements enable medical practitioners to perform downstream testing and analysis with enhanced efficiency. The company sells its products online and has established a strategic partnership with Agilent Technologies.
Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip.
It was founded in 2008 and headquartered in St Louis, Missouri.
At Synthomics, we are committed to driving life sciences innovation at the most basic level through the selling of reagents, and instrumentation that significantly improves upon key oligonucleotide synthesis needs for applications such as NGS, Gene Synthesis, Gene Editing, PCR, and DNA Data Storage.
Our "Green Machine" instrument reduces the cost of DNA synthesis by a factor of 20X-100X, while at the same shortening turn-around-times, minimizing waste, and improving quality.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.